Zelira Therapeutics (ZLDAF) Stock Price, News & Analysis

Company Overview

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Key Stats

• Today's Range: $0.29 to $0.29
• 50-Day Range: $0.29 to $0.38
• 52-Week Range: $0.19 to $0.55
• Volume: N/A
• Average Volume: 314 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZLDAF Stock Analysis - Frequently Asked Questions

How have ZLDAF shares performed this year?

Zelira Therapeutics' stock was trading at $0.3830 on January 1st, 2025. Since then, ZLDAF shares have decreased by 25.0% and is now trading at $0.2873.
View the best growth stocks for 2025 here.

When did Zelira Therapeutics' stock split?

Zelira Therapeutics's stock reverse split on the morning of Monday, April 18th 2022. The 1-175 reverse split was announced on Monday, April 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Zelira Therapeutics?

Shares of ZLDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ZLDAF
• CIK: N/A
• Web: www.zeldatherapeutics.com
• Phone: (186) 558-0886
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A